SPH.L

Sinclair Pharma Plc
Sinclair Pharma PLC - Disclosure under Rule 2.10(c)
17th October 2018, 06:00
TwitterFacebookLinkedIn
To continue viewing RNS, please confirm that you are a Private Investor*

* A Private Investor is a recipient of the information who meets all of the conditions set out below, the recipient:

  1. Obtains access to the information in a personal capacity;
  2. Is not required to be regulated or supervised by a body concerned with the regulation or supervision of investment or financial services;
  3. Is not currently registered or qualified as a professional securities trader or investment adviser with any national or state exchange, regulatory authority, professional association or recognised professional body;
  4. Does not currently act in any capacity as an investment adviser, whether or not they have at some time been qualified to do so;
  5. Uses the information solely in relation to the management of their personal funds and not as a trader to the public or for the investment of corporate funds;
  6. Does not distribute, republish or otherwise provide any information or derived works to any third party in any manner or use or process information or derived works for any commercial purposes.
RNS Number : 2661E
Sinclair Pharma PLC
17 October 2018
 

Toscafund Asset Management LLP

Disclosure under Rule 2.10(c) of The City Code on Takeovers and Mergers

 

 

Toscafund Asset Management LLP ("Toscafund") provided a non-binding letter of intent to Huadong Medicine Aesthetics Investment (Hong Kong) Limited on 28 August 2018 regarding the proposed acquisition of Sinclair Pharma plc as referred to in the announcement of the recommended cash offer on 18 September 2018. 

 

The non-binding letter of intent was for 148,613,603 ordinary shares of 1p each in Sinclair Pharma plc.

 

In accordance with Rule 2.10(c) of The City Code on Takeovers and Mergers it is today confirmed that following a disposal Toscafund no longer intends to comply with the letter of intent in respect of 92,000,000 ordinary shares of 1p each in Sinclair Pharma plc. The non-binding letter of intent issued on 28 August 2018 still applies to 56,613,603 ordinary shares of 1p each in Sinclair Pharma plc.


This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
END
 
 
MSCGGGWCUUPRGRQ ]]>
TwitterFacebookLinkedIn